Publications and Presentations

Abstract PF401. Presented on June 15, 2018 at 23rd Congress of the European Hematology Association (EHA)

Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted Cytotoxic Tn Lymphocytes) for Rituximab-Refractory Post-Transplant EBV+ Lymphomas: A Single Center Experience
View Citation > View Poster >
Susan Prockop, Ekaterina Doubrovina, Amy Feng, Guenther Koehne, Parastoo Dahi, Esperanza Papadopoulos, Craig Sauter, Stephanie Suser, Willis Navarro, Akshay Sudhindra, Richard O’Reilly

Am J Transplant 2016;16 (suppl 3; abstr 575). Presented on June 13, 2016 at 2016 American Transplant Congress, Boston, MA..

Banked EBV-Specific T-Cells for Treatment of Rituximab Refractory EBV+ B-Cell Lymphoma in Solid Organ Transplantation Recipients View Citation >
Prockop S, Doubrovina E, Sauter C, Suser S, O’Reilly R.

Abstract 3012. Presented on June 6, 2016 at 2016 American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Treatment of EBV+ nasopharyngeal carcinoma with banked EBV-specific cytotoxic T cells
View Citation >
Susan Prockop, Ekatarina Doubrovina, Shrujal S. Baxi, Virginia Escobedo, Stephanie Suser, Victoria Szenes, David G. Pfister, Richard J. O’Reilly

J Clin Oncol 33, 2015 (suppl; abstr 10016). Presented on June 1st, 2015 at the 2015 American Society of Clinical Oncology Annual Meeting, Chicago, IL.

Banked EBV-specific T-cells from HLA-partially matched normal donors to induce durable remissions of rituximab refractory EBV+ B-cell lymphomas post hematopoietic and organ allografts. View Citation >
Prockop, S. et al.

Abstract CT107. Presented on April 19th, 2015 at the American Association for Cancer Research Annual Meeting 2015, Philadelphia, PA.

Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder. View Citation >
Prockop, S. et al.

Haematologica. 2014 Feb; 99(2): 346–352.doi: 10.3324/haematol.2013.087338

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. View Citation >
Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al.

Bone Marrow Transplantation (2014) 49, 280–286; doi:10.1038/bmt.2013.170; Epub 2013 Nov 11

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. View Citation >
Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, et al.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. View Citation >
Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, et al.

Blood. 2010 Dec 2;116(23):5045-9. doi: 10.1182/blood-2010-04-281873. Epub 2010 Sep 8.

Successful treatment of EBV-associated post-transplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. View Citation >
Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G and O’Reilly RJ.

Clinical data on EBV targeted T-cell therapy for MS

Presented on October 26, 2017 at MSParis 2017 Congress, the 7th Joint Meeting of the ECTRIMS and ACTRIMS

Safety and clinical improvement in a phase I trial of autologous Epstein–Barr virus-specific T cell therapy in patients with progressive multiple sclerosis View Citation >
Pender M, Khanna R, et al.

Abstract P4.408, Presented on April 26, 2017 at AAN in Boston, MA.

Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein–Barr virus-specific T cell therapy: Interim results of a phase I trial View Citation >
Pender M, Csurhes P, Smith C, Douglas N, Neller M, Beagley L, Rehan S, Hopkins T, Thompson K, Blum S, Green K, Ioannides Z, Coulthard A, Hooper K, Burrows S, Khanna R

Multiple Sclerosis (Houndmills, Basingstoke, England). 2014;20(11):1541-1544. doi:10.1177/1352458514521888

Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis View Citation >
Pender M, Csurhes P, Smith C, et al.

EBV and MS connection – Epidemiology

Annals of neurology. 2010;67(6):824-830. doi:10.1002/ana.21978.

Primary Infection with the Epstein-Barr Virus and Risk of Multiple Sclerosis. View Citation >
Levin LI, Munger KL, O’Reilly EJ, Falk KI, Ascherio A.

Neurology Neuroimmunology & Neuroinflammation. 2017;4(2):e318. doi:10.1212/NXI.0000000000000318.

Epstein-Barr–negative MS: a true phenomenon? View Citation >
Dobson R, Kuhle J, Middeldorp J, Giovannoni G.

Neurology Neuroimmunology & Neuroinflammation. 2017;4(3):e308. doi:10.1212/NXI.0000000000000308.

Time correlation between mononucleosis and initial symptoms of MS. View Citation >
Endriz J, Ho PP, Steinman L.

PLoS ONE. 2010;5(9):e12496. doi:10.1371/journal.pone.0012496

An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. View Citation >
Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV

EBV presence in Brain of MS patients

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 7;5(4):e466. doi: 10.1212/NXI.0000000000000466. eCollection 2018 Jul

Molecular signature of Epstein-Barr virus infection in MS brain lesions View Citation >
Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH

Neurology. 2012 Jan 3;78(1):15-23. doi: 10.1212/WNL.0b013e31823ed057.

Association of innate immune activation with latent Epstein-Barr Virus in active MS lesions. View Citation >

The Journal of Experimental Medicine.. 2007;204(12):2899-2912. doi:10.1084/jem.20071030.

Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. View Citation >
Serafini B, Rosicarelli B, Franciotta D, et al.

MS disease course and EBV activity

Annals of neurology. 2010;67(2):159-169.doi:10.1002/ana.21886.

Elevated EBNA1 Immune Responses Predict Conversion to Multiple Sclerosis. View Citation >
Lünemann JD, Tintoré M, Messmer B, et al.

EBV potential connection to the Pathophysiology of MS

Clinical & Translational Immunology. 2017;6(1):e126-. doi:10.1038/cti.2016.87.

Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis. View Citation >
Pender MP, Csurhes PA, Burrows JM, Burrows SR.

The Neuroscientist. 2011;17(4):351-367. doi:10.1177/1073858410381531.

The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. View Citation >
Pender MP.

Abstract 3157 presented December 6, 2015 at the American Society of Hematology Annual Meeting 2015.

Successful Treatment of Refractory CMV Chorioretinitis and Meningoencephalitis with Adoptive Transfer of Third Party CMVpp65 Specific T-Cell Lines. View Citation >
Prockop SE, Hasan AN, Doubrovina E, Castro-Malaspina HR, Barker JN, Dahi PB, Boulad F, Kernan NA, Koehne G, Sauter CS, Kiss S, Patel M, Suser S, O’Reilly RJ.

Biol Blood Marrow Transplant. 2015 May 29. pii: S1083-8791(15)00372-9. doi: 10.1016/j.bbmt.2015.05.015. [Epub ahead of print]

Immunotherapy with Donor T- Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent CMV Infection or Viremia. View Citation >
Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, O’Reilly RJ.

Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):80-2. doi: 10.3928/23258160-20150101-14.

Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion. View Citation >
Gupta MP, Coombs P, Prockop SE, Hasan AA, Doubrovina E, O’Reilly RJ, Cohen SH, Park SS, Kiss S.

Blood (ASH Annual Meeting Abstracts) 2014: Abstract 309. Presented on December 8th, 2014 at the American Society of Hematology Annual Meeting 2014.

Banked, GMP Grade Third Party T-Cell Lines Specific for CMVpp65 Epitopes Presented By Certain Prevalent HLA Alleles More Consistently Clear CMV Infections in a Genetically Heterogeneous Population of HSCT Recipients. View Citation >
Hasan AN, Prockop SE, Koehne G, Doubrovina E, and O’Reilly RJ.

Blood (ASH Annual Meeting Abstracts) 2014: Abstract 184. Presented on December 7th, 2014 at the American Society of Hematology Annual Meeting 2014.

Third Party Donor Derived CMV Specific T Cells for the Treatment of Refractory CMV Viremia and Disease after Hematopoietic Stem Cell Transplant. View Citation >
Prockop SE, Hasan AN, Koehne G, Doubrovina E, Sauter CS, Barker JN, Baroudy K, Boulad F, Giralt G, Khalaf R, Kernan NA, Papadopoulos EB, Ponce DM, Scaradavou A, Suser S, Wasilewski G, and O’Reilly RJ.

Abstract presented March 28, 2017 at EBMT in Marseille, France

Wilms’ Tumor 1 Protein is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches in Patients With Relapsed/Refractory Myeloma and Plasma Cell Leukemia View Citation >
Koehne G, Devlin S, Doubrovina E, Landau H, Hassouon H, Lesokhin A, Lendvai N, Chung D, Landgren O, Giralt S, O’Reilly RJ.

Abstract 98 presented December 5, 2015 at the American Society of Hematology Annual Meeting 2015.

Wilms’ Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches. View Citation >
Koehne G, Kosuri S, Doubrovina E, Dao T, Scott A, Jungbluth A, O’Reilly RJ.

Blood. 2013 Jan 10; 121(2):308-17. doi: 10.1182/blood-2012-06-435040. Epub 2012 Nov 16

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. View Citation >
Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias. View Citation >
Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O’Reilly RJ.